Trial Title:
ACT-TIL and ANV419 for Advanced Melanoma.
NCT ID:
NCT05869539
Condition:
Advanced Melanoma
Conditions: Official terms:
Melanoma
Conditions: Keywords:
adoptive cell therapy
tumor-infiltrating lymphocytes
ANV419
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Combination of Tumor-infiltrating lymphocyte transfer with ANV419
Description:
The study uses a personalized IMP (investigational medicinal product), i.e. TIL product
in combination with ANV419.
Day 0: Autologous TIL: (minimum 5 x 10^9 and up to 2x 10^11 lymphocytes) administered
intravenously over 20 to 30 minutes.
Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion.
Actual body weight will be used to calculate the dose of ANV419.
Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to
calculate the dose of ANV419.
Arm group label:
Tumor-infiltrating lymphocyte transfer combined with ANV419
Summary:
In this study we aim to investigate safety and tolerability of tumor-infiltrating
lymphocytes (TIL) adoptive cell therapy (ACT) incorporation in-vivo TIL expansion with
ANV419 in patients with advanced melanoma
Detailed description:
In brief, this trial consists of four study periods: screening, pre-treatment, treatment,
and observational follow-up.
In the screening period, patients are screened for trial eligibility. In the
pre-treatment period, patients have excisional biopsy/surgical resection of tumor
lesion(s) (tumor collection) and TILs are expanded from this lesion/these lesions (TIL
expansion). Patients are permitted to receive bridging therapy outside of the study
protocol.
In the treatment period, patients have TIL-ACT. TIL-ACT includes a detailed procedure of
preparative chemotherapy, followed by transfer of the TIL product, followed by in-vivo
TIL expansion with ANV419 (2 doses). TIL transfer is defined as day 0 in the study
protocol. Patients have an End of Treatment visit (14 days after the last study
treatment), a safety follow-up (30 days after the last study treatment) and an efficacy
follow up, which is the End of Study visit (day +90).
Thereafter, patients will transfer to observational follow-up, which is conducted every 3
months until 1 year after TIL transfer.
Patients who terminate the study prematurely during any of the treatment period due to
e.g., disease progression, toxicity, patient wish, etc. will also transfer to
observational follow-up.
The regimen (TIL-ACT with ANV419) has not been tested. Review by the IDSMB (independent
data safety monitoring board) will be performed after 3 patients (safety check).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Patients who meet all the following criteria will be eligible to participate in the
study:
- Must provide written informed consent for the study.
- Must be able to comply with the study protocol as judged by the investigator.
- Are ≥ 18 years. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
- Have pathologically confirmed stage III (unresectable) or stage IV (metastatic)
cutaneous melanoma, as per the American Joint Committee on Cancer staging system,
8th edition, and have experienced disease progression and exhausted all approved
treatment option with curative intent.
- Have received at least one prior systemic treatment line of PD-(L)1 inhibitor and
BRAF/MEK inhibition in case of BRAFV600 mutated melanoma. Adjuvant systemic
treatment terminated ≥12 months prior to diagnosis of metastatic disease is not
counted as a treatment line.
- Accessible tumor lesion(s) for TIL collection and willingness of the patient to
undergo biopsy/resection of tumor lesion(s).
- Measurable disease as per RECIST v1.1 (following biopsy/resection of tumor lesion(s)
for TIL collection).
- Adequate organ function (pulmonary, cardiovascular, hematological, hepatic, and
renal function) per investigator's judgment. Cardiac stress testing is mandatory for
all patients with underlying cardiac conditions and patients with age ≥50 years. 10.
Female patients of childbearing potential must have a negative serum pregnancy test
at the screening visit and a negative serum pregnancy test within 72 hours prior to
start of preparative chemotherapy (day -7 in the study protocol).
- Female patients who are not postmenopausal, and who have not undergone surgical
sterilization, must agree to use highly effective methods of contraception during
the entire study period and for 6 months after the last dose of study drug. They
must also agree not to donate eggs (ova, oocytes) during the same timeframe.
- Male patients with partners of childbearing potential must agree to use highly
effective methods of contraception and barrier contraception (condom) during the
entire study period and for 6 months after the last dose of study drug. They must
also agree not to donate sperm during the same timeframe.
Exclusion Criteria:
- LDH (lactate dehydrogenase) ≥ 2x upper limit of normal (ULN).
- Life-expectancy ≤ 3 months per investigator's judgment.
- Have not recovered (i.e., ≤ Grade 1 or at baseline with the exception of alopecia or
fatigue [up to Grade 2 allowed]) from immune-related adverse events (irAEs)
resulting from prior immunotherapies. Patients who have endocrine immune-related AEs
controlled by replacement therapy (i.e., hypothyroidism) due to previous treatment
are eligible provided replacement therapy has been initiated and toxicity has
returned to Grade 1.
- Have not recovered (i.e., ≤ Grade 1 or at baseline) from toxicities due to a
previously administered chemotherapy, targeted small molecule therapy, or radiation
therapy.
Note: If the patient received major surgery, they must have recovered adequately from the
toxicity and/or complications from the intervention prior to starting study drug. Major
surgery is defined as any surgery requiring entrance into a body cavity (e.g., chest,
abdomen, or brain), organ removal, normal anatomy alteration, or joint replacement. Minor
surgery is defined as any surgery in which skin, mucosa, or connective tissue sections
are altered (e.g., biopsy, cataract, endoscopic procedures, etc.).
- Have been diagnosed with uveal/ocular or mucosal melanoma.
- Have a known additional malignancy (including all in-situ carcinoma) that is
progressing or required active treatment within 2 years prior to enrollment.
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of
the skin that have undergone potentially curative therapy and have no evidence of
disease or in situ cervical cancer in patients who completed cancer-directed therapy
or have evidence of stable disease and do not require active treatment.
- Have active central nervous system metastases and/or carcinomatous meningitis
regardless of clinical stability. Patients with previously treated brain metastases
may participate provided they are stable (without evidence of progression by imaging
for at least 4 weeks prior to study treatment (day -7 in the study protocol), and
any neurologic symptom has returned to baseline. New or enlarging brain metastases,
as well as the use of steroids (≥10 mg of prednisone daily or equivalent) within the
last 7 days prior to study drug are excluded.
- Have a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to study treatment (day
-7 in the study protocol).
- Are receiving systemic steroid ≥10 mg of prednisone daily or equivalent for any
reason. Local steroid therapies (e.g., otic, ophthalmic, intra-articular, or inhaled
medications) are acceptable. -
- Have an active autoimmune disease that has required systemic treatment in the past 2
years (i.e., with use of disease modifying agents, corticosteroids, or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment. 11. Have a
known history of, or any evidence of active, non-infectious pneumonitis.
- Have an active (measurable) and uncontrolled (unresponsive to current therapy)
infectious disease (bacterial, fungal, viral, protozoic).
- Have a history of an acute coronary event (e.g., myocardial infarction) within 3
months prior to study treatment (day -7 in the study protocol), uncontrolled and
symptomatic coronary artery disease, or congestive heart failure New York Heart
Association Class III/IV.
- Have an average QTc interval > 470 msec at ECG-screening.
- Have a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the study, interfere with the
patient's participation for the full duration of the study, or it is not in the best
interest of the patient to participate, in the opinion of the treating investigator.
- Have known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the study.
- Are pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the Screening Visit through 6 months
after the last dose of study drug.
- Are known to be human immunodeficiency virus (HIV) positive (or tests positive for
HIV 1 or 2 at Screening), unless the following criteria are met:
1. Cluster of differentiation (CD)4+ lymphocyte count > 350 μL.
2. Had no history of acquired immunodeficiency syndrome (AIDS)-defining
opportunistic infections within the past 12 months.
3. Have been on established anti-retroviral therapy for at least 4 weeks.
4. Have an HIV viral load of > 400 copies/mL prior to study treatment (day -7 in
the study protocol).
Note: Patients on strong cytochrome P450 (CYP)3A4 inhibitors or strong CYP3A4 inducers
must be switched to an alternate effective anti-retroviral therapy regimen prior to study
treatment or are excluded if regimen prior to study treatment cannot be altered.
- Have uncontrolled hepatitis B infection or hepatitis C infection. Note: Patients
with hepatitis B (positive hepatitis B surface antigen) who have controlled
infection (serum hepatitis B virus DNA by polymerase chain reaction that is below
the limit of detection and receiving anti-viral therapy for hepatitis B) are
permitted. Patients with controlled infections must undergo periodic monitoring of
hepatitis B virus DNA. Note: Patients with hepatitis C (positive hepatitis C virus
antibody) who have controlled infection (undetectable hepatitis C virus RNA by
polymerase chain reaction either spontaneously or in response to a successful prior
course of anti-hepatitis C virus therapy) are permitted.
- Have received a live vaccine within 30 days of study treatment (day -7 in the study
protocol). Note: Seasonal influenza vaccines for injection are generally inactivated
flu vaccines and are allowed; however, intranasal influenza vaccines (e.g.,
Flu-Mist®) are live attenuated vaccines, and are not allowed.
- Are positive for SARS-CoV2.
- Known hypersensitivity to any of the study therapies or drugs used for TIL
production. - Any other conditions/diseases, dysfunctions, and/or findings, that
would contraindicate the use of any of the study interventions or therapies.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University Hospital Basel
Address:
City:
Basel
Zip:
4031
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Heinz Läubli, Prof.
Phone:
+41 61 265 50 74
Email:
heinz.laeubli@usb.ch
Contact backup:
Last name:
David König, Dr. med.
Phone:
+41 61 265 50 74
Email:
david.koenig@usb.ch
Investigator:
Last name:
Heinz Läubli, Prof.
Email:
Principal Investigator
Investigator:
Last name:
David König, Dr. med.
Email:
Sub-Investigator
Investigator:
Last name:
Benjamin Kasenda, PD Dr.
Email:
Sub-Investigator
Start date:
June 21, 2023
Completion date:
June 2025
Lead sponsor:
Agency:
University Hospital, Basel, Switzerland
Agency class:
Other
Collaborator:
Agency:
Anaveon AG
Agency class:
Industry
Source:
University Hospital, Basel, Switzerland
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05869539
